Aquestive Therapeutics (AQST) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• Aquestive Therapeutics is scheduled to release its Q2 2025 earnings results on August 5th, with analysts projecting earnings of ($0.18) per share and revenue of $11.32 million.
• The company has recently seen a significant change in institutional ownership, with AQR Capital Management increasing its position by 12.2%, now holding 32.45% of the stock.
• A number of analysts have issued positive ratings for AQST, with a consensus rating of "Buy" and a price target averaging $10.14.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.18) per share and revenue of $11.32 million for the quarter. Aquestive Therapeutics has set its FY 2025 guidance at EPS.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.07). The company had revenue of $8.72 million during the quarter, compared to analyst estimates of $12.23 million. On average, analysts expect Aquestive Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Aquestive Therapeutics Price Performance

NASDAQ:AQST traded down $0.02 during trading hours on Friday, reaching $3.82. 941,366 shares of the stock were exchanged, compared to its average volume of 1,520,320. The firm has a 50 day moving average of $3.51 and a 200 day moving average of $3.08. Aquestive Therapeutics has a twelve month low of $2.12 and a twelve month high of $5.80. The stock has a market cap of $379.44 million, a PE ratio of -6.47 and a beta of 1.97.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Aquestive Therapeutics stock. AQR Capital Management LLC boosted its stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 12.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 129,019 shares of the company's stock after acquiring an additional 14,025 shares during the period. AQR Capital Management LLC owned 0.13% of Aquestive Therapeutics worth $374,000 at the end of the most recent quarter. 32.45% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Oppenheimer assumed coverage on Aquestive Therapeutics in a report on Monday, June 2nd. They issued an "outperform" rating and a $7.00 price objective for the company. HC Wainwright reissued a "buy" rating and set a $10.00 target price on shares of Aquestive Therapeutics in a report on Tuesday, June 17th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $10.14.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.